The CDC Finally Has a Boss Again. Now Comes the Hard Part.
The Senate just confirmed Erica Schwartz as CDC director after nearly a year without permanent leadership, and the biggest question isn't about her impressive resume. It's whether she'll stand up to her own boss on vaccines.
The Centers for Disease Control and Prevention has been running without a permanent director for nearly a year. Think of it like a hospital operating without a chief of surgery: technically functional, practically chaotic. That era just ended.
Dr. Erica Schwartz was confirmed by the Senate on August 5, 2026 as the new CDC director, squeaking through on a 51–44 vote that split almost entirely along party lines. Senator Tim Kaine was the only Democrat to cross the aisle and vote yes. The confirmation makes Schwartz only the second CDC director to require Senate confirmation, a requirement created by the 2023 Consolidated Appropriations Act.
But the vote itself isn't the story. The story is what happens next.
A Resume That Reads Like a Tom Clancy Novel
Schwartz isn't a lab scientist who's spent decades peering into microscopes. She's an operator. Her career has taken her from the Navy to the Coast Guard to the Surgeon General's office to the C-suite of UnitedHealthcare, with stops at nearly every major public health crisis of the last two decades along the way.
She holds a medical degree from Brown, a master's in public health, a law degree, and board certification in preventive medicine. During her time in the U.S. Public Health Service, she worked on Hurricane Katrina, the 2009 H1N1 pandemic, the Haiti earthquake, Deepwater Horizon, and the West Africa Ebola outbreak. That's not a resume; that's a disaster movie marathon.
From 2019 to 2021, she served as Deputy Surgeon General and helped build the federal government's COVID-19 testing infrastructure, including drive-through testing sites across all 50 states. After leaving government, she moved into the private sector, serving as president of insurance solutions at UnitedHealthcare and sitting on the boards of companies like Aveanna Healthcare and Butterfly Network.
The private-sector chapter is where critics start raising eyebrows. To address concerns, Schwartz pledged to resign her outside board roles, sell healthcare-related holdings, and recuse herself from matters involving former employers.
More from this issue
View full issue →
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
